Entresto is often prescribed alongside beta-blockers and mineralocorticoid receptor antagonists. However, it should not be combined with other ACE inhibitors, ARBs, or neprilysin inhibitors due to the risk of excessive blood-pressure lowering and angio-edema. Always review your full medication list with a pharmacist or prescriber.
A persistent dry cough is more commonly associated with ACE inhibitors than with Entresto. If you experience a new cough, report it to your healthcare provider; they may assess whether a dosage adjustment or an alternative therapy is required.
Yes. Entresto adds sacubitril, a neprilysin inhibitor, to valsartan. Clinical trials have shown that this combination reduces cardiovascular death and heart-failure hospitalisation more effectively than valsartan alone.
Yes, but keep the medication in its original packaging with the prescription label clearly visible. Carry a copy of the prescription and a letter from your doctor if you are traveling to countries with strict medication import rules.
Entresto can raise serum potassium and slightly increase creatinine levels, especially after the initial dose. Labs should be interpreted with awareness of these potential changes, and follow-up testing is recommended.
A low-salt diet is advisable to complement the natriuretic effect of sacubitril. Additionally, limit high-potassium foods (e.g., bananas, oranges) if your potassium levels are borderline high.
A minimum of 36 hours should elapse between stopping an ACE inhibitor and starting Entresto. This interval helps minimise the risk of angio-edema.
Mild to moderate hepatic impairment does not contraindicate Entresto, but clinicians often start at the lowest dose and monitor liver function tests periodically.
Entresto is listed on the NHS formulary for patients with HFrEF who meet specific clinical criteria, such as persistent symptoms despite optimal standard therapy. Eligibility is determined by the prescribing clinician.
Entresto tablets are round, film-coated, and typically bear the imprint “ENT 97/103”. The exact colour and markings may vary slightly between manufacturers, but the imprint helps confirm authenticity.
Entresto is a prescription medication that combines two active ingredients-sacubitril and valsartan-into a single pill. It belongs to the heart and blood pressure therapeutic class and is approved for the treatment of certain types of chronic heart failure in the United Kingdom. The product is available as a 97 mg/103 mg pill.
Entresto targets two complementary pathways that influence cardiovascular function:
Together, the combination produces a greater reduction in blood pressure and cardiac stress than either component alone. The onset of action occurs within hours of the first dose, with steady-state effects typically reached after several days of consistent dosing. The drug is absorbed well from the gastrointestinal tract, and both components are metabolized primarily by the liver before renal excretion.
Entresto is approved in the UK for use in adults with chronic heart failure with reduced ejection fraction (HFrEF), a condition where the heart’s pumping ability is diminished (ejection fraction ≤ 40%). Clinical guidelines from the National Institute for Health and Care Excellence (NICE) recommend Entresto as a first-line therapy for patients who remain symptomatic despite standard treatment with an ACE inhibitor, beta-blocker, and a mineralocorticoid receptor antagonist.
Key points of the approved indication:
This article provides educational information about Entresto and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
